Mid-Morning Market Update: Markets Edge Lower; US Wholesale Inventories Rise 2.5% In February
U.S. stocks traded mostly lower this morning, with the Nasdaq Composite dropping 100 points on Friday.
Why BioCryst Pharmaceuticals Stock Is Plunging Today
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) shares are trading significantly lower Friday after the company paused enrollment in clinical trials with BCX9930 while it investigates elevated serum creatinine levels seen in some patients.
BioCryst Pauses Enrollment in BCX9930 Clinical Trials While The Company Investigates Elevated Serum Creatinine Levels Seen In Some Patients
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company has paused enrollment in clinical trials with BCX9930 while the company investigates elevated serum creatinine levels seen in
Earnings Scheduled For February 23, 2022
Companies Reporting Before The Bell
• Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter.
BioCryst Begins Patient Enrollment In RENEW Proof-Of-Concept Trial Evaluating BCX9930 For Patients With Renal Complement-Mediated Diseases
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the enrollment of the first patient in the RENEW proof-of-concept basket study with its oral Factor D inhibitor, BCX9930, in patients with C3 glomerulopathy
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Is BioCryst (BCRX) Ready to Breakout to New Highs on Recent Catalysts?
By Ben Rabizadeh
– Fundamentals well positioned with $1B peak sales forecast for Orladeyo and $300M influx of cash from royalty deals
– Potential catalysts: update on Orladeyo sales with Q4 results on Feb. 23; BCX9930 trial enrollment underway and expect updates on progress
Trader Jon Najarian Highlights Unusual Option Activity On Cameco, BioCryst
-CNBC's "Fast Money: Halftime Report"
If You Invested $1000 In This Stock 10 Years Ago, Here’s How Much You Would Have Today
BioCryst Pharmaceuticals (NASDAQ:BCRX) has outperformed the market over the past 10 years by 5.6% on an annualized basis.
BioCryst Is On Fire: What Do Options Traders Expect Next?
Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) surged 11.16% to close Tuesday’s trading at $16.43, after the company announced upbeat sales of its oral therapy drug, Orladeyo.